Impact of pre‐treatment prostate tissue androgen content on the prediction of castration‐resistant prostate cancer development in patients treated with primary androgen deprivation therapy

Great advances in tissue androgen analysis using liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) have made it possible to evaluate the tissue androgen content from a single needle prostate biopsy specimen. In this study, we investigated if pre‐treatment androgen content in prostate biopsy specimens could predict their response to primary androgen deprivation therapy (ADT) and future castration‐resistant prostate cancer (CRPC). One‐hundred and sixty‐five prostate cancer patients who received primary ADT were enrolled. They had received multiple core prostate needle biopsy at diagnosis, and an additional one needle biopsy specimen was obtained for tissue androgen determination using LC‐MS/MS. The patients' prostate specific antigen (PSA) values were periodically followed during the treatment and patients were determined to have CRPC when their PSA value increased continuously to 25% above the nadir and a 2.0 ng/mL increase. A significant correlation was found between PSA value decline velocity (PSA half‐time) after ADT and pre‐ADT tissue androgen content. Twenty‐three patients were determined to have CRPC. These CRPC patients had a significantly high concentration of tissue T (p < 0.01) and low concentration of tissue 5α‐dihydrotestosterone (DHT) (p < 0.01), resulting in a higher tissue T/DHT ratio (p < 0.001). A multivariate Cox proportional hazard model revealed the pre‐ADT tissue T/DHT ratio and Gleason score as independent predictors for CRPC development. By using the two statistically significant variables, the relative risk of CRPC development could be calculated. The results of this study suggest that the evaluation of prostate androgen content in a single needle biopsy specimen may be useful to predict future CRPC development after primary ADT. Further studies are required for the clinical application of T/DHT ratio evaluation.

[1]  H. Yamanaka,et al.  Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy , 2011, Prostate Cancer and Prostatic Diseases.

[2]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[3]  C. Massard,et al.  Changing therapeutic paradigms in castrate-resistant prostate cancer. , 2010, Clinical genitourinary cancer.

[4]  D. Tindall,et al.  Effect of dutasteride on the risk of prostate cancer. , 2010, The New England journal of medicine.

[5]  M. Numazawa,et al.  Development of highly sensitive quantification method for testosterone and dihydrotestosterone in human serum and prostate tissue by liquid chromatography–electrospray ionization tandem mass spectrometry , 2009, Steroids.

[6]  O. Soldin,et al.  Steroid hormone analysis by tandem mass spectrometry. , 2009, Clinical chemistry.

[7]  C. Kwak,et al.  Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer. , 2009, The Journal of urology.

[8]  C. Tangen,et al.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Christina Wang,et al.  Validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: Interference and comparison with established methods , 2008, Steroids.

[10]  M. Gleave,et al.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.

[11]  Y. Shibata,et al.  Effect of castration monotherapy on the levels of adrenal androgens in cancerous prostatic tissues , 2008, Steroids.

[12]  Thomas J. Smith,et al.  Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Kota Takahashi,et al.  Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. , 2006, The Journal of urology.

[14]  Kota Takahashi,et al.  The Influence of Androgen Deprivation Therapy on Dihydrotestosterone Levels in the Prostatic Tissue of Patients with Prostate Cancer , 2004, Clinical Cancer Research.

[15]  E. Small,et al.  Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Fujita,et al.  The Adrenal Androgen Androstenediol Is Present in Prostate Cancer Tissue after Androgen Deprivation Therapy and Activates Mutated Androgen Receptor , 2004, Cancer Research.

[17]  Jun Luo,et al.  Decreased gene expression of steroid 5 alpha‐reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinoma , 2003, The Prostate.

[18]  I. Thompson,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[19]  F. S. French,et al.  Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. , 2001, Cancer research.

[20]  J Isola,et al.  Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. , 1997, Cancer research.

[21]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[22]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[23]  T. G. Shrivastav,et al.  Influence of different combinations of antibodies and penicillinase-labeled testosterone derivatives on sensitivity and specificity of immunoassays , 1992, Steroids.

[24]  F. Labrie,et al.  Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. , 1989, Journal of steroid biochemistry.

[25]  C. Brendler,et al.  Discrimination between normal, hyperplastic and malignant human prostatic tissues by enzymatic profiles. , 1985, The Journal of urology.

[26]  J. Drago,et al.  Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma , 1984, Cancer.

[27]  P. Walsh,et al.  Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal. , 1983, The Journal of clinical investigation.

[28]  D Rodbard,et al.  Statistical characterization of the random errors in the radioimmunoassay dose--response variable. , 1976, Clinical chemistry.

[29]  C. Huggins,et al.  Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. , 1941, CA: a cancer journal for clinicians.